AUTHORS
Xiangrui Meng, MD, Lanfang Li2, Zheng Song3, Zhengzi Qian4, Lihua Qiu5, Xianlin Duan6, Songyun Zhao7, Huilai Zhang, PhD8
AFFILIATIONS
1 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
2 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
3 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
4 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
5 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
6 JW Therapeutics (Shanghai) Co. Ltd, Shanghai, China
7 JW Therapeutics (Shanghai) Co. Ltd, Shanghai, China
8 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
ABSTRACT
Background: Relma-cel, a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy, is an approved treatment for relapsed or refractory (R/R) large B-Cell lymphoma (LBCL). To reduce manufacturing costs and enhance supply chain stability, an in-house lentiviral vector manufacturing process was established. Two post-approval bridging studies (a prospective investigator initiated trial [IIT] and an investigational New Drug [IND] application trial) were conducted to evaluate the safety and efficacy of relma-cel manufactured using the domestically produced lentiviral vector (JWLV011).
Aims: To assess the efficacy, safety and pharmacokinetic (PK)/ pharmcodynamic (PD) profiles of relma-cel manufactured with JWLV011 in adult patients with R/R LBCL.
Methods: Both studies employed identical inclusion and exclusion criteria and enrolled adults (≥18 years) with histologically confirmed R/R LBCL who had relapsed or progressed after ≥2 prior systemic therapies, including an anthracycline-containing regimen and anti-CD20 monoclonal antibody, or following autologous stem cell transplantation. Patients underwent lymphodepleting chemotherapy consisting of cyclophosphamide (250 mg/m2/day × 3 days) and fludarabine (25 mg/m2/day × 3 days), followed by a single infusion of relma-cel at a dose of 100 × 106 CAR+ T cells. The primary endpoint was investigator-assessed objective response rate (ORR) at 3 months post-infusion.
Results: As of the data cutoff dates (IIT: Oct 16, 2025; IND: July 13, 2026), 26 patients underwent leukapheresis, and 22 received relma-cel infusion. The median age was 58 years (range: 35–76; 31.8% ≥65 years), and 63.6% were male. At baseline, 50.0% had an International Prognostic Index (IPI) score 3-5, 9.1% had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1, and 9.1% had Bulky Disease lesion≥7.5cm in diameter. A total of 45.4% of patients had received at least three prior lines of systemic therapy. Overall, 50% had relapsed disease, and 68.2% were refractory to their most recent therapy; 50% received bridging therapy.
In the modified intent to treatment (mITT) population (n=22), the investigator-assessed overall response rate (ORR) at 3 months was 63.6%, with a complete response rate (CRR) of 36.4%, meeting the primary endpoint. The best investigator-assessed ORR was 72.7%, with a best CRR of 50.0%. After follow up 12 months, the progression-free survival (PFS) rate for all patients was 40.4%; among those achieving a complete response (CR), the PFS rate was 71.6%. Median overall survival (OS) and duration of response (DOR) were not reached, the 12-month OS rate for all patients was 77.3% (Figure 1).
In the Pharmacokinetic Analysis Set (PKS) population, based on qPCR assessment, peak cellular concentrations in subjects occurred between Days 8 and 15, with a median Tmax of 11 days. The median Cmax was 38,430.50 copies/μg, and the median AUC1-29 was 273,609.15 day·copies/μg. These key pharmacokinetic parameters were consistent with those from previous clinical studies using existing overseas vectors in patients with relapsed/refractory large B-cell lymphoma.
Relma-cel manufactured with JWLV011 demonstrated a manageable safety profile with no treatment-related deaths, or study discontinuations due to adverse events. All patients experienced treatment-related adverse events (TEAE), 18.2% developed serious TEAE. Cytokine release syndrome occurred in 90.9% of patients, most (95%) has grade 1-2. No patient developed neurological toxicities.
Conclusions: Relma-cel manufactured using the domestically produced lentiviral vector demonstrated favorable efficacy and a manageable safety profile in adult patients with R/R LBCL. These findings support the feasibility of in-house lentiviral vector manufacturing without compromising clinical performance.
DISCLOSURES
Xiangrui Meng, MD: No relevant conflicts of interest to declare.